Rectal Cancer

Rectal cancer in brief

Rectal cancer, also known as cancer of the rectum or rectal carcinoma, is a common cancer in Germany. Cancer of the colon and rectum is the second most common cancer in women and the third most common in men; about one third of these tumors affect the rectum. The average age at diagnosis is between 70 and 75 years, and men are affected somewhat more often. Rectal and colon cancer are often considered together. However, they differ in some respects, above all in their treatment.

Rectal cancer at a glance

Frequency
Colorectal cancer: second most common cancer in women, third most common in men; about one third affects the rectum
Typical age
On average 70 to 75 years, men affected somewhat more often
Most common type
Adenocarcinoma (more than 95 %)
Early detection
Entitled to a colonoscopy from age 50

What exactly is rectal cancer?

This article deals with cancer of the rectum. The rectum is the last roughly 16 cm (about 6 inches) of the bowel before the anus. It is divided into an upper, middle, and lower third; the location of the tumor plays an important role in treatment. More than 95 % of patients have an adenocarcinoma, which arises from the glandular cells of the mucous membrane. Like colon cancer, rectal cancer usually develops over years from benign precursors (polyps). If these are found during screening, they are removed. However, there are also other ways in which colon and rectal cancer can develop.

Why do I have rectal cancer?

The risk factors for rectal cancer are very similar to those for colon cancer:

  • Certain hereditary conditions: However, these account for only about 3 to 5 % of all colorectal cancers. They include, for example, Lynch syndrome (HNPCC) and familial adenomatous polyposis (FAP).
  • Colon or rectal cancer in one or more first-degree relatives, especially if the disease occurred before the age of 50

There are also known lifestyle factors that promote colon and rectal cancer:

  • Smoking and high alcohol consumption
  • Diet: low in fiber, high in fat, with a large share of red meat and processed sausage products and a small share of vegetables and fruit
  • Overweight and lack of exercise

Although these factors can increase the risk, this does not mean that every person with these risk factors will inevitably develop rectal cancer – and most people who develop it had none of these risk factors.

Symptoms of rectal cancer

In early stages, there are often no symptoms. Colon cancer and rectal cancer have similar symptoms, but some things differ:

  • Blood in the stool: In rectal cancer, bright red, fresh blood on the stool is more typical. Blood from higher sections of the bowel, by contrast, has often already clotted and tends to turn the stool dark. Note: Fresh blood in the stool can also have more harmless causes, e.g. hemorrhoids – but it should always be checked out.
  • Changes in bowel habits: In rectal cancer, the narrowing of the rectum can lead to very thin stools (so-called "pencil stools"); there can also be a frequent urge to have a bowel movement that can no longer be held back
  • Pain, cramps
  • Bowel obstruction (ileus): when the tumor completely blocks the bowel lumen, i.e. the inside of the bowel – an emergency

General symptoms can also occur, such as unintended weight loss and a drop in energy and performance.

Some of the symptoms are very nonspecific and can also occur with other diseases. That is why it is important to see a doctor if you notice any signs.

When is rectal cancer treated?

Outside of screening, rectal cancer is often only discovered at later stages. The diagnosis is confirmed by a colonoscopy with a tissue sample. Magnetic resonance imaging (MRI) of the pelvis and computed tomography are then used to determine how deeply the tumor has grown into the bowel wall and whether lymph nodes or other organs are affected. This determines whether pretreatment is needed before surgery. The therapy is recommended individually by the .

There is also an established early detection program for rectal and colon cancer. In Germany, women and men aged 50 and over are entitled to a complete colonoscopy. If benign polyps are found, they are removed right away. If the colonoscopy is unremarkable, it is repeated after 10 years. Alternatively, from age 50 a stool test for hidden blood can be done (every year up to age 54, every two years after that). If there is a family history, screening starts earlier.

How is rectal cancer treated?

The therapy depends on the stage of the disease and other individual factors. Different treatment approaches can be used. These include:

  • Surgical resection (removal): There are different surgical procedures. A distinction is made between procedures that preserve the sphincter muscle and thus continence, and those that require a permanent artificial bowel outlet (stoma) – the latter mainly for tumors located very low. Often a temporary stoma is created, which is later reversed.
  • Chemotherapy: Different drugs can be used here. In more advanced stages, chemotherapy is now usually given before surgery (neoadjuvant), often together with radiation ("total neoadjuvant therapy").
  • Radiation: Unlike in colon cancer, radiation is frequently used in rectal cancer. It is usually given before surgery as chemoradiotherapy, i.e. combined with chemotherapy, to shrink the tumor and prevent relapses in the pelvis.
  • Immunotherapy: checkpoint inhibitors, which support the immune system in fighting the cancer – in the small group of tumors with so-called mismatch repair deficiency (microsatellite instability), they are exceptionally effective
  • Watch and wait: that is, waiting and monitoring. If the tumor disappears completely as a result of pretreatment (clinical complete remission), surgery can be avoided in selected cases and the rectum monitored closely.

How exactly have clinical trials changed the treatment landscape for rectal cancer?

Clinical trials have markedly improved the treatment of rectal cancer. The German study group CAO/ARO/AIO has specialized in rectal cancer and has published groundbreaking trials over the last 20 years. Two examples are:

  • CAO/ARO/AIO-04: The trial examined in 1,236 patients whether adding oxaliplatin to chemoradiotherapy before surgery and to chemotherapy after surgery improves outcomes. It showed that the combination of fluorouracil and oxaliplatin allows longer than fluorouracil alone.
  • CAO/ARO/AIO-12: a trial of the concept of moving all of the therapy to before surgery (total neoadjuvant therapy). It divided 306 patients into two groups. One group first received chemotherapy (induction chemotherapy) followed by chemoradiotherapy. The other group first received chemoradiotherapy, followed by chemotherapy (consolidation chemotherapy). With the second sequence, the tumor had more often disappeared completely (pathological complete remission in 25 % instead of 17 %). This means that no cancer cells could be detected under the microscope in the tissue removed during surgery. According to the current guideline, chemotherapy is given for 3 to 4.5 months with FOLFOX or CAPOX.

The group is also currently conducting trials on rectal cancer. Interested in taking part in clinical trials? Then take a look here at the current trials in Germany.

There are also trials investigating new approaches such as immunotherapy for rectal cancer. One example is a 2022 trial of immunotherapy with the antibody dostarlimab: in all of the first 12 patients with a particular tumor feature (mismatch repair deficiency, about 5 to 10 % of rectal cancers), the tumor disappeared completely with immunotherapy – without surgery and without radiation. These results have since been confirmed in a larger number of patients.

This information is not a substitute for a conversation with your doctor.